Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of April 2025, specifically detailing share repurchases executed on April 3, 2025. The company is a Foreign Private Issuer filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing focuses exclusively on share buyback activity and does not report revenue, profit, cash flow, margins, or debt levels.
- Shares Purchased (April 3, 2025): 739,200 ordinary shares.
- Price Range: Lowest price paid was 1,446.50 GBp; highest price paid was 1,486.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,461.92 GBp.
- Total Buyback Since Feb 24, 2025: 20,425,637 ordinary shares.
- Treasury Shares Held: 189,495,940 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,125,725,792 ordinary shares.
- Total Voting Rights: 4,125,725,792.
Material Changes
The filing details a continuation of an existing share buyback programme. The purchase on April 3, 2025, was executed pursuant to a non-discretionary agreement entered into with Citigroup Global Markets Limited on February 24, 2025. All purchased shares are held as Treasury shares. There are no material changes to the company's financial position or operations reported in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 24, 2025 (20,425,637 shares).
- Confirm the updated count of Treasury shares held (189,495,940 shares).
- Check the denominator for shareholder notification calculations under FCA Disclosure Guidance and Transparency Rules (4,125,725,792 voting rights).
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors associated with forward-looking statements.